Our partner is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. The company brings significant drug discovery and development expertise to this challenge, complementary to over a decade of research by academic collaborators, to evaluate the role of this family of receptors in cancer.

This executive leader played a critical role in shaping our partner’s strategy, while interfacing with investors and partners. They cultivated the existing pipeline and maneuvered preclinical assets through the clinical process. They also managed an IND for the lead candidate (treatment of Acute Myeloid Leukemia -AML) in Q2 2020.